Date:3/30/2009

roperty and equipment, net 310,365 55,088 Patents, net of accumulated amortization of $38,588 and $110,599 14,433 32,371 Deposit 35,625 35,625 Total assets $12,261,236 $16,541,095 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses $710,881 $1,046,537 Accrued salaries and benefits 304,756 362,334 Income taxes payable - 50,738 Deferred revenue 39,347 15,165 Total current liabilities 1,054,984 1,474,774 Deferred compensation 660,000 609,000 Deferred rent 136,736 6,531 Total liabilities 1,851,720 2,090,305 Commitments and contingencies - - Stockholders' equity Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued and outstanding - - Common stock, $0.005 par value, 50,000,000 shares authorized; 14,437,600 and 14,399,140 issued, 14,357,162 and 14,318,702 outstanding at December 31, 2008 and 2007, respectively 72,188 71,996 Paid-in capital in excess of par value 27,602,486 27,508,418 Treasury stock, 80,438 shares, at cost at December 31, 2008 and 2007, respectively (464,786) (464,786) Accumulated deficit (16,800,372) (12,664,838) Total stockholders' equity 10,409,516 14,450,790 Total liabilities and st
'/>"/>

SOURCE Spherix Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients